Sekar Kathiresan is building Verve Therapeutics Inc. around the concept of a one-and-done treatment for cardiovascular disease because only half of patients are disciplined enough to take a statin every day. “That’s a huge issue for durable cholesterol lowering after a heart attack,” Verve’s CEO and co-founder told BioWorld.
LONDON – A remodeled Rexgenero Ltd. has launched as an integrated cell and gene therapy specialist, following integration of a French biotech acquired last year and a commitment from the company’s two shareholders to invest £40 million (US$54 million).
Lantern Pharma Inc., a Dallas-based cancer medicines developer using a machine learning platform to accelerate its work, is raising $60 million through a public offering priced at $14 per share (NASDAQ:LTRN).
Dublin – IO Biotech ApS raised €127 million (US$154.7 million) in a series B round to fund a potentially pivotal trial of its combination of cancer vaccines in first-line metastatic melanoma. The Copenhagen, Denmark-based company is one of a number of firms fueling a mini-resurgence in immuno-oncology in the early weeks of the new year, as new data and new insights are prompting additional investments in an area that some had thought was already oversubscribed.
Tessera Therapeutics Inc., a Cambridge, Mass.-based company working to "write therapeutic instructions into the genome," has raised $230 million in series B financing to back its development of potential cures and treatments for cardiovascular, oncological, neurodegenerative and infectious diseases.
RSS
